Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRNX Crinetics Pharmaceuticals	$31.93 -0.2%	$31.00	$24.10 ▼ $62.53	$3.00B	0.25	821,194 shs	598,277 shs
EGRX Eagle Pharmaceuticals	$3.55 -2.7%	$2.35	$1.50 ▼ $3.87	$46.10M	0.83	8,170 shs	12,073 shs
MIRM Mirum Pharmaceuticals	$52.66 -0.7%	$47.19	$36.20 ▼ $54.23	$2.63B	0.97	460,810 shs	320,943 shs
RLMD Relmada Therapeutics	$0.61 -9.0%	$0.61	$0.24 ▼ $4.37	$22.24M	0.59	970,833 shs	88,211 shs
SIGA Siga Technologies	$6.77 -1.9%	$6.18	$4.95 ▼ $12.83	$492.94M	0.94	717,685 shs	329,296 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRNX Crinetics Pharmaceuticals	-1.05%	+7.08%	-3.30%	+9.89%	-37.03%
EGRX Eagle Pharmaceuticals	-2.74%	+18.33%	+69.05%	+195.83%	-41.23%
MIRM Mirum Pharmaceuticals	-0.84%	+6.17%	+8.23%	+33.93%	+47.58%
RLMD Relmada Therapeutics	+9.44%	+6.87%	-15.41%	+126.77%	-84.27%
SIGA Siga Technologies	0.00%	+2.45%	+10.93%	+15.97%	-19.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRNX Crinetics Pharmaceuticals	3.5865 of 5 stars	3.4	0.0	3.7	2.5	2.5	0.0
EGRX Eagle Pharmaceuticals	2.6375 of 5 stars	0.0	3.0	3.9	0.6	3.3	0.0
MIRM Mirum Pharmaceuticals	2.9814 of 5 stars	2.6	0.0	4.2	1.5	1.7	0.6
RLMD Relmada Therapeutics	4.6111 of 5 stars	3.1	5.0	4.4	0.0	4.2	1.3
SIGA Siga Technologies	1.5144 of 5 stars	0.0	1.0	0.0	1.9	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRNX Crinetics Pharmaceuticals	2.80	Moderate Buy	$69.50	117.66% Upside
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	3.13	Buy	$65.50	24.38% Upside
RLMD Relmada Therapeutics	2.25	Hold	$5.00	719.67% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest EGRX, SIGA, RLMD, CRNX, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	MIRM Mirum Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/10/2025	CRNX Crinetics Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$36.00
6/27/2025	CRNX Crinetics Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
5/19/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$73.00
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$73.00 ➝ $77.00
5/9/2025	MIRM Mirum Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$74.00 ➝ $76.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRNX Crinetics Pharmaceuticals	$1.04M	2,874.62	N/A	N/A	$14.29 per share	2.23
EGRX Eagle Pharmaceuticals	$257.55M	0.18	$8.88 per share	0.40	N/A	∞
MIRM Mirum Pharmaceuticals	$336.89M	7.74	N/A	N/A	$4.70 per share	11.20
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.18 per share	N/A
SIGA Siga Technologies	$138.72M	3.49	$0.82 per share	8.25	$3.02 per share	2.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRNX Crinetics Pharmaceuticals	-$298.41M	-$3.82	0.00	N/A	N/A	N/A	-30.95%	-28.12%	8/6/2025 (Estimated)
EGRX Eagle Pharmaceuticals	$35.64M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.61	0.00	N/A	N/A	-20.39%	-33.63%	-11.50%	8/6/2025 (Estimated)
RLMD Relmada Therapeutics	-$79.98M	-$2.51	0.00	N/A	N/A	N/A	-181.26%	-151.23%	8/6/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$0.67	10.30	5.42	N/A	40.30%	25.21%	22.05%	7/30/2025 (Estimated)

Latest EGRX, SIGA, RLMD, CRNX, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	MIRM Mirum Pharmaceuticals	-$0.31	N/A	N/A	N/A	$107.91 million	N/A
8/6/2025	Q2 2025	RLMD Relmada Therapeutics	-$0.25	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
5/12/2025	Q1 2025	RLMD Relmada Therapeutics	-$0.31	-$0.58	-$0.27	-$0.58	N/A	N/A
5/8/2025	Q1 2025	CRNX Crinetics Pharmaceuticals	-$0.99	-$1.04	-$0.05	-$1.04	$0.10 million	$0.36 million
5/8/2025	Q1 2025	SIGA Siga Technologies	N/A	-$0.01	N/A	-$0.01	N/A	$7.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRNX Crinetics Pharmaceuticals	N/A	22.53	22.53
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	1.32	3.22	3.04
RLMD Relmada Therapeutics	N/A	5.29	5.29
SIGA Siga Technologies	N/A	8.40	6.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRNX Crinetics Pharmaceuticals	98.51%
EGRX Eagle Pharmaceuticals	85.36%
MIRM Mirum Pharmaceuticals	N/A
RLMD Relmada Therapeutics	45.24%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
CRNX Crinetics Pharmaceuticals	4.60%
EGRX Eagle Pharmaceuticals	28.90%
MIRM Mirum Pharmaceuticals	14.36%
RLMD Relmada Therapeutics	20.70%
SIGA Siga Technologies	1.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRNX Crinetics Pharmaceuticals	210	93.63 million	89.32 million	Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
MIRM Mirum Pharmaceuticals	140	49.53 million	42.42 million	Optionable
RLMD Relmada Therapeutics	10	33.19 million	26.32 million	Optionable
SIGA Siga Technologies	40	71.44 million	70.05 million	Optionable

EGRX, SIGA, RLMD, CRNX, and MIRM Headlines

Recent News About These Companies

Investors Purchase High Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

July 10 at 2:21 AM | americanbankingnews.com

Siga Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)

July 10 at 2:20 AM | marketbeat.com

Siga Technologies Inc. (SIGA) Laps the Stock Market: Here's Why

July 9 at 6:46 PM | zacks.com

SIGA Technologies Inc Dividends - Morningstar

July 8 at 7:29 PM | morningstar.comM

Why Siga Technologies Inc. (SIGA) Outpaced the Stock Market Today

June 26, 2025 | zacks.com

Investors Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

June 26, 2025 | marketbeat.com

New nuclear fuel cladding survive 3,452°F, 6 times hotter than normal reactors

June 25, 2025 | msn.com

General Atomics Achieves Another Milestone in Silicon Carbide Composite Nuclear Fuel Rod Technology

June 24, 2025 | indystar.comI

Here's Why Siga Technologies Inc. (SIGA) Fell More Than Broader Market

June 20, 2025 | zacks.com

Undiscovered Gems In US Market Including SIGA Technologies And 2 Other Small Caps

June 17, 2025 | finance.yahoo.com

Bank of America Corp DE Sells 367,682 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)

June 16, 2025 | marketbeat.com

Why Siga Technologies Inc. (SIGA) Dipped More Than Broader Market Today

June 13, 2025 | zacks.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Shares Bought by Harbor Capital Advisors Inc.

June 13, 2025 | marketbeat.com

Traders Buy High Volume of Call Options on SIGA Technologies (NASDAQ:SIGA)

June 12, 2025 | marketbeat.com

We Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster Earnings

May 16, 2025 | finance.yahoo.com

Undiscovered Gems in the US Market for May 2025

May 15, 2025 | finance.yahoo.com

SIGA Technologies First Quarter 2025 Earnings: US$0.006 loss per share (vs US$0.14 profit in 1Q 2024)

May 10, 2025 | finance.yahoo.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2025 Earnings Call Transcript

May 9, 2025 | msn.com

SIGA Reports Financial Results for Three Months Ended March 31, 2025

May 8, 2025 | globenewswire.com

Calculating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)

May 2, 2025 | finance.yahoo.com

Siga Technologies Inc. (SIGA) Stock Declines While Market Improves: Some Information for Investors

May 1, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, SIGA, RLMD, CRNX, and MIRM Company Descriptions

Crinetics Pharmaceuticals NASDAQ:CRNX

$31.93 -0.06 (-0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$31.92 0.00 (-0.02%)

As of 05:23 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Eagle Pharmaceuticals NASDAQ:EGRX

$3.55 -0.10 (-2.74%)

As of 07/10/2025 02:50 PM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Mirum Pharmaceuticals NASDAQ:MIRM

$52.66 -0.35 (-0.66%)

Closing price 04:00 PM Eastern

Extended Trading

$53.50 +0.85 (+1.60%)

As of 07:30 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Relmada Therapeutics NASDAQ:RLMD

$0.61 -0.06 (-8.97%)

Closing price 04:00 PM Eastern

Extended Trading

$0.61 +0.00 (+0.16%)

As of 07:46 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Siga Technologies NASDAQ:SIGA

$6.77 -0.13 (-1.88%)

Closing price 04:00 PM Eastern

Extended Trading

$6.88 +0.11 (+1.55%)

As of 07:49 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time